DB-1310

DRUG2 trials

Sponsors

DualityBio Inc., Synnovation Therapeutics, Inc.

Conditions

Advanced Solid Tumor

Phase 1

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

RecruitingNCT05785741

DualityBio Inc.Advanced Solid Tumor

Start: 2023-08-17End: 2028-04-30Target: 1000Updated: 2026-04-06

SNV1521 in Participants With Advanced Solid Tumors

RecruitingNCT06220864

Synnovation Therapeutics, Inc.Advanced Solid Tumor

Start: 2024-02-23End: 2027-12-01Target: 400Updated: 2026-06-25

Related Papers

Abstract PS4-06-17: First clinical data of DB-1310 (HER3-targeted antibody-drug-conjugate), in patients with pretreated hormone receptor-positive/HER2-negative breast cancer: efficacy and safety data from a phase 1/2a trial

Clinical Cancer Research2026-02-17

DB-1310, a HER3-targeted ADC, in pts with advanced solid tumors: Preliminary results from the phase 1/2a trial.

Journal of Clinical Oncology2025-05-283 citations

Abstract CT168: A phase 1/2a, multicenter, open-label, non-randomized first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1310 (a HER3-targeting ADC) in patients with advanced/metastatic solid tumors

Cancer Research2024-04-05